Sign in
4

Changes in Ownership

Dianthus Therapeutics, Inc. /DE/ Filed Acc 0001992324-26-000008

EVP, CFO & CBO sold 31,249 shares at an average $101.03 ($3,157,151)

  • EVP, CFO & CBO acquired 31,249 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Savitz Ryan EVP, CFO & CBO 2026-07-09 Option exercise 10b5-1 +31,249 $21.77 $680,291 31,249 D
Savitz Ryan EVP, CFO & CBO 2026-07-09 Sale 10b5-1 −10,354 $100.22 $1,037,678 20,895 D
Savitz Ryan EVP, CFO & CBO 2026-07-09 Sale 10b5-1 −15,329 $101.24 $1,551,908 5,566 D
Savitz Ryan EVP, CFO & CBO 2026-07-09 Sale 10b5-1 −5,566 $101.97 $567,565 0 D
Derivatives
Savitz Ryan EVP, CFO & CBO 2026-07-09 Option exercise · Stock Option (Right to Buy) 10b5-1 −31,249 68,751 D
Open-market sales · 31,249 sh · avg $101.03 · $3,157,151
Loading xslF345X06/ownership.xml…